Pfizer takes Johnson & Johnson to court for its anticompetitive actions regarding the Ramicade drug
Date: 2017-09-22   Author: Ojaswita Kutepatil  Category: #news

Pfizer takes Johnson & Johnson to court for its anticompetitive actions regarding the Ramicade drug

Two of the most globally reputed pharma companies, Pfizer and Johnson & Johnson are squaring off a new front in their legal battles over a rheumatoid arthritis drug.

According to reports, the world’s largest drugmaker, Pfizer, is suing Johnson & Johnson for implementing illegal anti-competitive practices to thwart its cheaper biosimilar of a powerful rheumatoid arthritis drug called Inflectra, launched in late 2016.  Sources revealed that the monopolistic actions of J&J have blocked over 70% of patients from having access to Pfizer’s copycat drug.

The brawl between Johnson & Johnson’s Remicade – the best-selling medicine by far and Pfizer’s biosimilar Inflectra has opened doors to another legal battle in the global biologics and biosimilars market, which, for the record, witnesses numerous legal encounters regarding costs, patents covering the drug, and other competitive barriers.

In this lawsuit filed by Pfizer, the company accused J&J for its anticompetitive actions that denied access to Pfizer’s biosimilar in the US market. It further undermined the company for lowering its drug prices and blocking Pfizer’s biosimilars from entering into the market, on purpose. For the record, biosimilars are intended to be a lower cost alternative and not the exact copy of the expensive drugs. Pfizer further claims that J&J made a deliberate attempt to suppress the competition in an aim to maintain its own monopoly for Remicade. In essence, Pfizer suspects J&J for violating the principal goals of the Federal Biologics Price Competition and Innovation Act.

Meanwhile, Johnson & Johnson has been selling Remicade for last two decades and it carries a sticker price of approximately USD 26,000 per annum for a typical user. While, on other hand, Pfizer’s Inflectra costs around USD 21,000 marking as much as a 40% discount. In the lawsuit, Pfizer has also mentioned that even with the discount, Remicade accounts for 96% of the overall market and generated USD 4.8 billion in US sales, because of J&J’s contracts between health insurers, hospitals, and clinics.

On the contrary, Johnson and Johnson dismissed the lawsuit filed by Pfizer, stating that it had no merit and the allegations are baseless. The president of Janssen Biotech, a division of J&J, further revealed that they are competing on value & price, and it is the fierce competition that is bringing down the overall cost of Remicade and not its anticompetitive behavior.



About Author


Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market res...

Read More

More from Ojaswita


Post Recommendents

Monoethylene Glycol Market 2020-2025 | Leading Key Players, Growth Avenue, Industry Outlook, Major Segment, Size, Share Report By 2025
Author: Rahul Sankrityayan

DecResearch has recently published a study titled ‘global Monoethylene glycol market research report’. In this report, analysts have provided a detailed evaluation of the global Monoethylene glycol market. ...


Phosphorescent Pigments Market 2020 | Dynamics, Forecast, Analysis and Supply Demand 2025
Author: Rahul Sankrityayan

DecResearch has recently published a study titled ‘global Phosphorescent pigments market research report’. In this report, analysts have provided a detailed evaluation of the global Phosphorescent pigments ...


Samsung’s Lifestyle TV lineup to come with eco-friendly packaging
Author: Saipriya Iyer

Samsung Electronics Co. Ltd., one of the leading South Korean electronics companies, has reportedly announced plans to introduce sustainable, eco-friendly packaging across its Lifestyle TV product portfolio, taking a s...